Abstracts tagged "IL-6"

Abstract Number: 1320 • 2013 ACR/ARHP Annual Meeting
Categorization Of Rheumatoid Arthritis Subjects By Rheumatoid Factor and Anti-Cyclic Citrullinated Autoantibody Status Identifies Rheumatoid Arthritis Subjects With Different Characteristics
Swati Modi¹, Mariely Nieves-Plaza², Donald M. Jones³, Erich R Wilkerson⁴, Christine L. Amity⁵, Kelly A. Reckley⁶, Ilinca D. Metes⁷, Jason Lyons⁸, Heather Eng⁹, Stephen R. Wisniewski⁹ and Marc C. Levesque¹⁰, ¹Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴Medicine, University of Pittsburgh, Pittsburgh, PA, ⁵Rheumatology & Clinical Immun, Univ of Pittsburgh, Pittsburgh, PA, ⁶Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁷Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁸School of Public Health, Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, ⁹Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ¹⁰Division of Rheumatology and Clinical Immunology, University of Pittsburgh Department of Medicine, Pittsburgh, PA
Background/Purpose: Rheumatoid factor (RF) and anti-citrullinated cyclic peptide (CCP) antibodies have been used to diagnose rheumatoid arthritis (RA) patients, although there is substantial heterogeneity among…
Abstract Number: 1279 • 2013 ACR/ARHP Annual Meeting
Anti-IL-6 Receptor Antibody Is Effective In Arthritis Regardless Of Obesity In Mouse Model
Miho Suzuki, Hiroto Yoshida and Yoshihiro Matsumoto, Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan
Background/Purpose: Compared with non-obese patients, obese patients with rheumatoid arthritis (RA) reportedly experience worsening of symptoms [Arthritis Care Res (Hoboken). 2013; 65: 78-87] and do…
Abstract Number: 150 • 2013 ACR/ARHP Annual Meeting
A Subset Of Osteoarthritis Individuals Has Elevated IL-6 Pathway Activation Associated With Worse Symptoms
Michael Kuziora¹, Zheng Liu², Brandon W. Higgs², Philip Brohawn², Kim Lehmann², Fernanda Pilataxi², Katie Streicher², Lydia Greenlees¹, Meina Liang³, Rozanne Lee⁴, Amy Schneider⁴, Raffaella Faggioni⁴, Yihong Yao² and Koustubh Ranade², ¹Translational Science, MedImmune, LLC, Gaithersburg, MD, ²Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ³Dmpk, MedImmune, LLC, Hayward, CA, ⁴DMPK, MedImmune, LLC, Hayward, CA
Background/Purpose: Elevated levels of the pro-inflammatory cytokine IL-6 have been found in the affected joint of patients with osteoarthritis (OA), although the prevalence of OA…
Abstract Number: 939 • 2013 ACR/ARHP Annual Meeting
Reduction Of Circulating Blood Neutrophils In Mice By Anti-IL-6R Alpha Monoclonal Antibody is Not Due To Apoptosis Or Blockade Of Neutrophil Differentiation
Ludmila Kelly, Vilma Decman and Dimitris Skokos, Research, Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Blockade of IL-6/IL-6Rα signaling is associated with a reduction of circulating neutrophils in the blood of patients treated with anti-IL-6Rα mAb but the mechanism…
Abstract Number: 2549 • 2013 ACR/ARHP Annual Meeting
Can Biomarkers Provide An Objective Standard Against Which To Assess Lupus Clinical Endpoint Measures?
Aikaterini Thanou¹, Melissa E. Munroe², Stan Kamp³, Joel M. Guthridge⁴, Judith A. James⁵ and Joan T. Merrill⁶, ¹Arthritis and Clinical Immmunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Clinical Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Despite the heterogeneity of SLE, specific pathways of immune dysregulation characterize significant subsets of patients. We examined cytokines reflecting IL6-TH17 pathology in lupus as…
Abstract Number: 915 • 2013 ACR/ARHP Annual Meeting
IL-6R Inhibition Reduces Activation Of Different Peripheral Memory B Cell Subsets In RA
Zafar Mahmood¹, Khalid Muhammad¹, Marc Schmalzing², Petra Roll³, Kathrina Eckert¹, Thomas Dörner⁴ and Hans-Peter Tony⁵, ¹Rheumatology and Clinical Immunology, University of Würzburg, Würzburg, Germany, ²Rheumatology/Clinical Immunology, University Hospital Würzburg, Würzburg, Germany, ³Rheumatology and Clinical immunology, University of Würzburg, Würzburg, Germany, ⁴CC12, Dept. Medicine/Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany, ⁵Rheumatology/Clinical Immunology, University of Würzburg, Würzburg, Germany
Background/Purpose: Enhanced B cell activity has been proposed as part of the pathogenesis of rheumatoid arthritis also based on the clinical experiences obtained by B…
Abstract Number: 2355 • 2013 ACR/ARHP Annual Meeting
Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Against The IL-6 Receptor Alpha: Using Acute Phase Reactants, Efficacy and Safety Parameters To Inform Phase 3 Dose Selection
Janet van Adelsberg¹, Steven P. Weinstein², Neil Graham³, Tanya Momtahen⁴, Chunpeng Fan⁵ and Stefano Fiore⁶, ¹Clinical Science, Regeneron Pharmaceutials, Inc., Tarrytown, NY, ²Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ³Program Direction, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Program Direction, Sanofi, Bridgewater, NJ, ⁵Biostatistics, Sanofi, Bridgewater, NJ, ⁶Clinical Science, Sanofi, Bridgewater, NJ
Background/Purpose: Sarilumab (SAR) is a fully human mAb directed against IL-6Rα. In phase 2 MOBILITY Part A (NCT01061736), SAR administered SC plus MTX (methotrexate 10-25…
Abstract Number: 667 • 2013 ACR/ARHP Annual Meeting
IL6 and CCL2 Co-Regulate Fibroblast Dependent Trans-Endothelial Migration Of Mononuclear Cells and Fibrotic Response In Scleroderma
Rebecca Alade¹, Korsa Khan², Xu Shiwen³, Christopher P. Denton⁴ and Voon Ong⁵, ¹Centre for Rheumatology and Connective Tissue Diseases,, UCL Medical School, London, United Kingdom, ²Centre for Rheumatology and Connective Tissue Diseases, UCL medical School, London, United Kingdom, ³Rheumatology, Royal Free Hospital, London, United Kingdom, ⁴Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ⁵Department of Rheumatology, UCL Medical School, London, England
Background/Purpose: IL6 is a key mediator recently implicated in activation of extracellular matrix (ECM) proteins in scleroderma (SSc) fibroblasts. CCL2 is a proinflammatory chemokine that…
Abstract Number: 2358 • 2013 ACR/ARHP Annual Meeting
Sarilumab, a Subcutaneously Administered, Fully Human Monoclonal Antibody Inhibitor Of The IL-6 Receptor Alpha: 12 Week Infection Rates By Level Of Circulating Neutrophils In Rheumatoid Arthritis and Ankylosing Spondylitis
Kevin L. Winthrop¹, Tanya Momtahen², Stefano Fiore³, Steven P. Weinstein⁴, Janet van Adelsberg⁵, Richard Wu⁶ and Neil Graham⁷, ¹Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ²Program Direction, Sanofi, Bridgewater, NJ, ³Clinical Science, Sanofi, Bridgewater, NJ, ⁴Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ⁵Clinical Science, Regeneron Pharmaceutials, Inc., Tarrytown, NY, ⁶BioStatistics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁷Program Direction, Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Sarilumab is a human monoclonal antibody directed against the alpha subunit of the IL-6 receptor (IL-6Rα). IL-6 blockade is associated with a reduction in…
Abstract Number: 653 • 2013 ACR/ARHP Annual Meeting
Norepinephrine-Induced IL-6 Regulates Fibrosis In Systemic Sclerosis
Sei-ichiro Motegi, Akihito Uehara, Kazuya Yamada, Akihiko Uchiyama, Sachiko Ogino, Yoko Yokoyama, Yuko Takeuchi and Osamu Ishikawa, Department of Dermatology, Gunma University Graduate School of Medicine, Gunma, Japan
Background/Purpose: Raynaud phenomenon is freaquently observed in patients of systemic sclerosis (SSc) and characterized by episodic vasospasm and ischemia of extremities in response to cold or…
Abstract Number: 2263 • 2013 ACR/ARHP Annual Meeting
ADAMTS5 Is a Biomarker For The Efficacy Prediction Of Tocilizumab In Rheumatoid Arthritis
Kensei Tsuzaka, Masako Takao and Jiro Nishida, Dept of Internal Medicine, Ichikawa General Hospital,TDC, Ichikawa, Chiba, Japan
a disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5) mRNA level. In this study presented here, we investigated whether the efficacy of tocilizumab (TCZ) for…
Abstract Number: 558 • 2013 ACR/ARHP Annual Meeting
Fli-1 Regulates Immune Cell Infiltration Through Affecting Local Chemokine Expression and IL-6 Expression In The Kidney Of Lupus Prone Mice
Shuzo Sato¹, Sarah Williams², Eva Karam³ and Xian Zhang⁴, ¹Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, ²Ralph H. Johnson VA Medical Center, Charleston, SC, ³Medicine, Medical University of South Carolina, Charleston, SC, ⁴Medicine, Medical University of South Carolina and Ralph H. Johnson VA Medical Center, Charleston, SC
Background/Purpose: Fli-1 expression level, a member of the Ets family of transcription factors, is a mitigating factor in the development of nephritis in murine models…
Abstract Number: 2213 • 2013 ACR/ARHP Annual Meeting
Anti-IL-6 Receptor Antibody Normalizes Both DKK-1 and Sclerostin As Wnt Inhibitors In a Mouse Model Of Collagen-Induced Arthritis
Hiroto Yoshida¹, Mika Yagoto¹, Miho Suzuki¹, Keisuke Tanaka¹, Isao Matsumoto², Takayuki Sumida³ and Yoshihiro Matsumoto¹, ¹Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ²Department of Internal Medicine, Faculty of Medicine,, University of Tsukuba, Tsukuba, Japan, ³Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
Background/Purpose: The Wnt pathway plays an important role in bone formation and regeneration. This pathway is regulated by several soluble inhibitors such as Dickkopf-1 (DKK-1)…
Abstract Number: 470 • 2013 ACR/ARHP Annual Meeting
Sarilumab, a Subcutaneously Administered, Fully Human Monoclonal Antibody Inhibitor Of The IL-6 Receptor Alpha: Relationship Between Inflammation Suppression and Changes In Cholesterol Levels
Christina Charles-Schoeman¹, Steven P. Weinstein², Janet van Adelsberg³, Tanya Momtahen⁴, Richard Wu⁵, Neil Graham⁶ and Stefano Fiore⁷, ¹Medicine-Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ³Clinical Science, Regeneron Pharmaceutials, Inc., Tarrytown, NY, ⁴Program Direction, Sanofi, Bridgewater, NJ, ⁵BioStatistics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁶Program Direction, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁷Clinical Science, Sanofi, Bridgewater, NJ
Background/Purpose: Sarilumab (SAR) is a fully human monoclonal antibody directed against the alpha subunit of the IL-6 receptor (IL-6Rα) which is currently being evaluated for…
Abstract Number: 2226 • 2013 ACR/ARHP Annual Meeting
Involvement Of Suppressor Of Cytokine Signaling In Anti-Arthritic Effect Induced By Anti-IL-6 Receptor Antibody
Miho Suzuki¹, Hiroto Yoshida¹, Keisuke Tanaka¹, Isao Matsumoto², Takayuki Sumida³ and Yoshihiro Matsumoto¹, ¹Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ²Department of Internal Medicine, Faculty of Medicine,, University of Tsukuba, Tsukuba, Japan, ³Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
Background/Purpose: In the treatment of rheumatoid arthritis (RA), biologics such as IL-6 and TNF inhibitors have high therapeutic efficacy with extended duration of effect [“LITHE…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].